Abstract 1831
Background
The potential antitumor effect of metformin (M) in breast cancer is being explored by several clinical studies, in early disease. In this phase II randomised study, we compare the efficacy of M plus first line chemotherapy (CT) versus CT in metastatic breast cancer (MBC).
Methods
126 non-diabetic women (ITT 122) with stage IV, HER2 negative BC, untreated with CT, were randomized to Arm A: AC (non-pegylated liposomal doxorubicin 60 mg/m2 + cyclofosfamide 600mg/m2, x 8 Q21 + metformin 2,000 mg pos daily until progression) vs Arm B: AC. The primary endpoint was progression free survival (PFS); 98 PFS events were required for 80% power. Secondary endpoints were overall survival (OS), safety and outcome by insulin resistance status (HOMA Index ≥2.5).
Results
122 patients are evaluable for primary endpoint. HOMA Index was > 2.5 in 57 patients (46.7%). At 39.6 months' median follow-up (range 1-71 months), 111 PFS events and 70 deaths had been observed. Median PFS was 9.4 months (95%CI 7.8-10.4) in Arm A (CT + M) and 10.1 (95%CI 7.7-11.5) in Arm B (CT), p= 0.61. 12 month PFS rate was 28.6% (95%CI: 17.4%-40.8%) in Arm A vs 37.1% (95%CI: 25.2%-49.0%) in Arm B. Overall, median PFS was 10.7 months (95%CI 9.6-12.8) in patients with HOMA Index
Conclusions
The present study does not provide evidence in support of an antitumor activity of M in combination with first line CT in MBC. Noteworthy, a significantly shorter PFS was observed in insulin-resistant patients (HOMA ≥2,5), without significant interaction with M. Further development of M in this setting is not warranted, while the adverse prognostic impact of insulin resistance needs to be addressed further.
Clinical trial identification
Eudract number 2009-014662-26 .Protocol version:13 May 2009 Amendment 1: 18/11/2010
Legal entity responsible for the study
IRST Meldola (FC), Italy
Funding
TEVA, Italian Association for Cancer Research (AIRC)
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
Single agent activity of DS-8201a, a HER2-targeting antibody-drug conjugate, in breast cancer patients previously treated with T-DM1: Phase 1 dose escalation
Presenter: Kenji Tamura
Session: Breast cancer, metastatic
Resources:
Abstract
Invited discussant abstracts LBA16, LBA17 and 224PD
Presenter: Cristina Saura
Session: Breast cancer, metastatic
Resources:
Presentation
Webcast
Invited discussant abstracts 228PD, 229PD, 230PD and 231PD
Presenter: Luis Costa
Session: Breast cancer, metastatic
Resources:
Presentation
Webcast
Invited discussant abstracts 222O and 223O
Presenter: Javier Cortes Castan
Session: Breast cancer, metastatic
Resources:
Presentation
Impact of palbociclib plus letrozole on health related quality of life (HRQOL) compared with letrozole alone in treatment naïve postmenopausal patients with ER+ HER2- metastatic breast cancer (MBC): results from PALOMA-2
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
Heritage, a phase III safety and efficacy trial of the proposed trastuzumab biosimilar, Myl-1401O vs trastuzumab
Presenter: Hope Rugo
Session: Breast cancer, metastatic
Resources:
Abstract
First line hormone therapy vs chemotherapy for HR+ HER2- metastatic breast cancer in the phase III STIC CTC trial: clinical choice and validity of CTC count
Presenter: Francois-Clement Bidard
Session: Breast cancer, metastatic
Resources:
Abstract
FALCON: A phase III randomised trial of fulvestrant 500 mg vs. anastrozole for hormone receptor-positive advanced breast cancer
Presenter: Matthew Ellis
Session: Breast cancer, metastatic
Resources:
Abstract
Everolimus use in breast cancer patients: a population-based study
Presenter: Mariana Chavez-Macgregor
Session: Breast cancer, metastatic
Resources:
Abstract
Efficacy and safety of BCD-022, trastuzumab biosimilar candidate, compared to herceptin: Results of international multicenter randomized double blind study in patients with HER2+ mBC
Presenter: Maria Shustova
Session: Breast cancer, metastatic
Resources:
Abstract